PE20240222A1 - Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion - Google Patents

Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Info

Publication number
PE20240222A1
PE20240222A1 PE2023001504A PE2023001504A PE20240222A1 PE 20240222 A1 PE20240222 A1 PE 20240222A1 PE 2023001504 A PE2023001504 A PE 2023001504A PE 2023001504 A PE2023001504 A PE 2023001504A PE 20240222 A1 PE20240222 A1 PE 20240222A1
Authority
PE
Peru
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
PE2023001504A
Other languages
English (en)
Spanish (es)
Inventor
Seok Cheol Yoo
Sun Lee
Duck Il Yun
Junghong Park
Hyun Ji Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20240222A1 publication Critical patent/PE20240222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2023001504A 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion PE20240222A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01
PCT/KR2021/017842 WO2022119269A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Publications (1)

Publication Number Publication Date
PE20240222A1 true PE20240222A1 (es) 2024-02-16

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001504A PE20240222A1 (es) 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Country Status (15)

Country Link
US (1) US20240000751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4257123A4 (cg-RX-API-DMAC7.html)
JP (1) JP7678106B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220077091A (cg-RX-API-DMAC7.html)
CN (1) CN116528852B (cg-RX-API-DMAC7.html)
AR (1) AR124178A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021390901B9 (cg-RX-API-DMAC7.html)
CA (1) CA3197405A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008265A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023005459A (cg-RX-API-DMAC7.html)
PE (1) PE20240222A1 (cg-RX-API-DMAC7.html)
TW (3) TW202600130A (cg-RX-API-DMAC7.html)
WO (1) WO2022119269A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305156B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901895B (zh) * 2021-06-15 2025-10-21 南韓商Lg化學股份有限公司 一種包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸的醫藥組成物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538102A (ja) * 2002-07-31 2005-12-15 ファルマシア・コーポレーション 低下された架橋を示すゼラチンカプセル
WO2006078948A2 (en) * 2005-01-21 2006-07-27 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Lg生命科學有限公司 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
CA3194595A1 (en) * 2020-11-04 2022-05-12 Seok Ju Lee Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
PE20240764A1 (es) * 2021-04-16 2024-04-17 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico

Also Published As

Publication number Publication date
CA3197405A1 (en) 2022-06-09
AU2024227367A1 (en) 2024-10-31
JP2023551712A (ja) 2023-12-12
MX2023005459A (es) 2023-05-23
TW202600130A (zh) 2026-01-01
TWI840721B (zh) 2024-05-01
EP4257123A4 (en) 2024-05-08
US20240000751A1 (en) 2024-01-04
AU2021390901A9 (en) 2024-05-23
TWI896975B (zh) 2025-09-11
WO2022119269A1 (ko) 2022-06-09
EP4257123A1 (en) 2023-10-11
ZA202305156B (en) 2024-09-25
TW202408496A (zh) 2024-03-01
AU2021390901A1 (en) 2023-06-08
AR124178A1 (es) 2023-02-22
KR20220077091A (ko) 2022-06-08
TW202228679A (zh) 2022-08-01
JP7678106B2 (ja) 2025-05-15
AU2021390901B2 (en) 2024-11-07
AU2021390901B9 (en) 2024-11-21
CO2023008265A2 (es) 2023-06-30
CL2023001215A1 (es) 2023-12-15
CN116528852A (zh) 2023-08-01
CN116528852B (zh) 2026-05-12

Similar Documents

Publication Publication Date Title
ES2928399T3 (es) Composición farmacéutica bactericida que comprende ibuprofeno
MX392901B (es) Tratamiento que comprende la administracion oral o gastrica de edaravona
PE42598A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
PH12021551035A1 (en) Pyrazoles as modulators of hemoglobin
JOP20240257A1 (ar) مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها
AR124178A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
US9096585B2 (en) Antiviral compounds and uses thereof
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.
US20220354825A1 (en) Pharmaceutical composition for prevention or treatment of inflammatory diseases comprising naphthoquinone derivative
Marcinkiewicz et al. Current opinion on the therapeutic capacity of taurine-containing halogen derivatives in infectious and inflammatory diseases
CN114712355B (zh) Rhps4在制备抑制金黄色葡萄球菌和铜绿假单胞菌药物中的应用
NO337768B1 (no) Væskeformig, farmasøytisk preparat av piperazinderivater, og minst ett konserveringsmiddel av parahydroksybenzoatestere
CO2024017734A2 (es) Compuesto novedoso y composición farmacéutica que comprende la misma como ingrediente activo
ZA202311237B (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
JP2009078977A (ja) 心筋の小胞体ストレス抑制剤
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
CO2022014273A2 (es) Medicamentos para fibrosis pulmonar que contienen derivado de pirazol
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
EP3936132A1 (en) Azelastine as antiviral treatment
US20090022686A1 (en) Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome
ES2289305T3 (es) Medicamento para el tratamiento del "sindrome de la respuesta inflamatoria sistemica".
US20220348605A1 (en) Antimicrobial compounds, compositions, and uses thereof
MX2024004372A (es) Formulacion oral.
de Paula et al. Letter by de Paula et al Regarding Article,“Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase”